Abstracts

Impact of an educational activity on the competence of oncologists and gastroenterologists regarding the application of molecular-guided therapies for the treatment of advanced cholangiocarcinoma

Background Cholangiocarcinoma (CCA) is a rare, aggressive cancer of the biliary tract with patients often having a poor prognosis and complex genetic heterogeneity. Foll...

06/27/2022

Comprehensive recurrence risk assessment after colectomy, for stage II and III colorectal cancer patients, using genetic profiling, microbiome, and circulating tumor markers

Background Colorectal cancer (CRC) incidence increases in the western population and is considered of a major public health issue. To date, patients’ prognosis is mainly...

06/27/2022

Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study

Background T-DXd is an antibody–drug conjugate consisting of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a topoisomerase I inhibitor. T-DXd is appr...

06/27/2022

Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow-up

Background Gastrointestinal lymphomas constitute 10-15% of non-Hodgkin´s Lymphomas and 30-40% of extra-nodal lymphomas. Primary gastric lymphoma (PGL) is the most common...

06/27/2022

Trial in progress: Neoadjuvant combination therapy of lenvatinib plus transcatheter arterial chemoembolization (TACE) for transplant-eligible patients with large hepatocellular carcinoma

Background Hepatocellular carcinoma HCC is the third leading cause of cancer death worldwide with more than 230,000 cases of HCC since 2000 and an estimated 42,000 new c...

A. Esmail ;

A. Saharia ;

Susheel K. Kodali , MD;

D. Victor ;

K. Heyne ;

R. Ghobrial ;

M. Abdelrahim ;

06/27/2022

Lenvatinib activates potential anti-tumor immunity by increasing infiltration of immune cells and interferon response in tumor microenvironment of advanced hepatocellular carcinoma

Background It has been reported that the combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, and an immune checkpoint inhibitor enhances the antitu...

H. Nelson ;

Y. Kato ;

M. Kimura ;

M. Yamauchi ;

N. Suzuki ;

A. Ono ;

H. Aikata ;

K. Amioka ;

K. Chayama ;

Y. Fujii ;

S. Uchikawa ;

H. Fujino ;

T. Nakahara ;

E. Murakami ;

W. Okamoto ;

T. Kawaoka ;

D. Miki ;

M. Tsuge ;

M. Imamura ;

06/27/2022

Real-world data in patients with localized esophageal and gastro-esophageal junction cancer undergoing surgery in France: Results from the FREGAT database

Background Esophageal cancer (EC) is the third most common digestive cancer in France with an incidence of 5450 new cases in 2018. All stages combined the prognosis rema...

06/27/2022

Inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine: A single-center study

Background The aim of the study was to examine the prognostic significance of inflammatory biomarkers in patients (pts) with locally advanced or metastatic pancreatic du...

06/27/2022

Using artificial intelligence CT-based methods to evaluate body composition for predicting survival outcomes in patients with colorectal cancer receiving PD-1 treatment

Background As for PFS, SMI [hazard ratio (HR) (95% CI): 1.041 ((1.003-1.081))], SMD [HR (95% CI): 1.113 (1.035-1.197)], and pre-therapeutic alkaline phosphatase (ALP) [H...

06/27/2022

Quality of life assessment in biliary tract cancer: A systematic review of phase 2 and 3 clinical trials published between 2010 and 2021

Background In the last decades quality of life (QoL) has emerged as a fundamental parameter in clinical trials to evaluate the impact of a drug, beyond traditional oncol...

06/27/2022